|
Arteriosclerosis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
In addition, CTRP9 downregulated the expressions of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α), two main proinflammatory cytokines in atherosclerosis.
|
30426302 |
2019 |
|
Arteriosclerosis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
However, whether the CTRP9 affects the activity of NLRP3 inflammasome during the atherosclerosis development remains unclear, which would be elucidated in the current study.
|
31727560 |
2019 |
|
Atherosclerosis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
However, whether the CTRP9 affects the activity of NLRP3 inflammasome during the atherosclerosis development remains unclear, which would be elucidated in the current study.
|
31727560 |
2019 |
|
Atherosclerosis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
In addition, CTRP9 downregulated the expressions of monocyte chemoattractant protein-1 (MCP-1) and tumor necrosis factor-alpha (TNF-α), two main proinflammatory cytokines in atherosclerosis.
|
30426302 |
2019 |
|
Coronary Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Conclusions This study provides the first evidence that the long-term existence of β<sub>1</sub>- AA mAb suppresses cardiac CTRP 9 expression and exaggerates cardiac remodeling, suggesting that CTRP 9 may be a novel therapeutic target against pathologic remodeling in β<sub>1</sub>- AA -positive patients with coronary heart disease.
|
30764693 |
2019 |
|
Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the latest advances regarding the roles of CTRP9 in atherosclerosis with an emphasis on its potential as a novel therapeutic target in cardiovascular disease.
|
30056359 |
2018 |
|
Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
These results show that CTRP9 protects against atherosclerosis by promoting cholesterol efflux to reduce the formation of foam cell in virtue of inducing autophagy in an AMPK/mTOR signaling pathway-dependent manner.
|
29979351 |
2018 |
|
Atherosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
These results show that CTRP9 protects against atherosclerosis by promoting cholesterol efflux to reduce the formation of foam cell in virtue of inducing autophagy in an AMPK/mTOR signaling pathway-dependent manner.
|
29979351 |
2018 |
|
Atherosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this review, we summarize the latest advances regarding the roles of CTRP9 in atherosclerosis with an emphasis on its potential as a novel therapeutic target in cardiovascular disease.
|
30056359 |
2018 |
|
Coronary Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Role of CTRP3, CTRP9 and MCP-1 for the evaluation of T2DM associated coronary artery disease in Egyptian postmenopausal females.
|
30557342 |
2018 |
|
Coronary Arteriosclerosis
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Circulating CTRP9 levels are significantly decreased in patients with coronary atherosclerosis disease.
|
30056359 |
2018 |
|
Coronary Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Association of circulating CTRP9 with soluble adhesion molecules and inflammatory markers in patients with type 2 diabetes mellitus and coronary artery disease.
|
29381773 |
2018 |
|
Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
CTRP9 independently trends in a different manner from HAN, and may reflect diabetic renal vascular risk in association with atherosclerosis and abnormal glucose metabolism besides of impaired vaso-relaxation in patients with T2DM.
|
26633552 |
2017 |
|
Atherosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
CTRP9 independently trends in a different manner from HAN, and may reflect diabetic renal vascular risk in association with atherosclerosis and abnormal glucose metabolism besides of impaired vaso-relaxation in patients with T2DM.
|
26633552 |
2017 |
|
Coronary Arteriosclerosis
|
0.050 |
Biomarker
|
disease |
BEFREE |
Circulating and coronary CTRP9 plays an important role in the inflammation and coronary atherosclerosis of CAD patients.
|
26457306 |
2015 |
|
Myocardial Infarction
|
0.040 |
Biomarker
|
disease |
BEFREE |
<b>Conclusions:</b> This study provides the first evidence that MI+CIH upregulates miR-214-3p, suppresses cardiac CTRP9 expression, and exacerbates cardiac remodeling, suggesting that CTRP9 may be a novel therapeutic target against pathologic remodeling in MI patients with OSA.
|
31694459 |
2020 |
|
Myocardial Infarction
|
0.040 |
Biomarker
|
disease |
BEFREE |
C1q/TNF-related protein-9 (CTRP9) has anti-inflammatory effects and can ameliorate heart function in mice after long-term myocardial infarction.
|
30953351 |
2019 |
|
Myocardial Infarction
|
0.040 |
Biomarker
|
disease |
BEFREE |
CTRP9 (C1q/tumor necrosis factor-related protein-9) as a secreted glycoprotein can reverse left ventricle remodeling post-MI, but its effects on MI-induced atrial inflammation, fibrosis, and associated AF are unknown.
|
31623508 |
2019 |
|
Coronary Artery Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Conclusions This study provides the first evidence that the long-term existence of β<sub>1</sub>- AA mAb suppresses cardiac CTRP 9 expression and exaggerates cardiac remodeling, suggesting that CTRP 9 may be a novel therapeutic target against pathologic remodeling in β<sub>1</sub>- AA -positive patients with coronary heart disease.
|
30764693 |
2019 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
In this review, we summarize the latest advances regarding the roles of CTRP9 in atherosclerosis with an emphasis on its potential as a novel therapeutic target in cardiovascular disease.
|
30056359 |
2018 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
As a novel adipokine, C1q/tumor necrosis factor-related protein-9 (CTRP9) has beneficial effects in cardiovascular disease.
|
29979351 |
2018 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The results revealed increased circulating levels of CTRP9 in T2DM and CAD individuals which suggests a compensatory response to insulin resistance, inflammatory milieu and endothelial dysfunction; however, more studies are needed to confirm this.
|
29381773 |
2018 |
|
Coronary Artery Disease
|
0.040 |
Biomarker
|
disease |
BEFREE |
Role of CTRP3, CTRP9 and MCP-1 for the evaluation of T2DM associated coronary artery disease in Egyptian postmenopausal females.
|
30557342 |
2018 |
|
Coronary Artery Disease
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The results revealed increased circulating levels of CTRP9 in T2DM and CAD individuals which suggests a compensatory response to insulin resistance, inflammatory milieu and endothelial dysfunction; however, more studies are needed to confirm this.
|
29381773 |
2018 |
|
Cardiovascular Diseases
|
0.040 |
Biomarker
|
group |
BEFREE |
C1q/TNF-related protein 9 (CTRP9) is a recently discovered adipokine that has been shown to have beneficial effects on glucose metabolism and vascular function, particularly in regard to cardiovascular disease.
|
28524645 |
2017 |